Photo by: Steven Depolo Is it really necessary to pay a fund manager 1.5% a year to buy you shares in GlaxoSmithKline? How hard can it be to recognise that GSK is a decent company with reasonable prospects over the long term and then to buy it at a time that it is not grossly over priced? […]